Prometic and Aventis Behring sign a development and collaboration agreement

06-Nov-2000

- Aventis Behring L.L.C. and ProMetic Life Sciences Inc. (ProMetic; Toronto TSE symbol PLI), announced today that they have signed a development and collaboration agreement that provides Aventis Behring access to ProMetic's unique protein purification technology. Aventis Behring will fund the development of a Mimetic LigandTM to isolate a specific high-value therapeutic protein from plasma. The Mimetic LigandTM will be generated from ProMetic's Intelligent Combinatorial Libraries and will be designed to enhance Aventis Behring's already rigorous therapeutic protein purification procedures.

"Aventis Behring is pleased to partner with ProMetic as they have an impressive track record for developing synthetic ligands with high capacity and selectivity for therapeutic proteins. We trust in ProMetic's ability to augment our manufacturing processes while meeting our stringent quality assurance requirements," said Dr. Fred Feldman, Vice President and Chief Scientist, Research and Development, Aventis Behring. "This agreement exemplifies Aventis Behring's continued commitment to innovating and supplying the highest quality therapeutic proteins for our patients around the world."

"We are particularly pleased that Aventis Behring, a global market leader in therapeutic proteins and recombinant products, has chosen ProMetic's advanced technology to further enhance its manufacturing process," commented Pierre Laurin, President and Chief Executive Officer of ProMetic. "This agreement further consolidates ProMetic's position in the plasma and recombinant protein purification market." Subject to regulatory approval, ProMetic anticipates that its annual revenues from currently active worldwide plasma-derived protein purification projects will exceed $50 million.

ProMetic owns proprietary enabling technology essential for use in large-scale drug purification, chemical genomics, proteomics, drug discovery and drug development. This technology can significantly reduce costs, increase yield and improve purity of existing and new bio-pharmaceutical products. ProMetic accomplishes this through strategic partnerships and in-house therapeutic development. The headquarters of ProMetic Life Sciences Inc. are in Montreal and it has operations in Canada, The United States and the UK. Its shares are traded on the Toronto Stock Exchange under the ticker symbol PLI. Additional information is available on the company's website: www.prometic.com.

Aventis Behring L.L.C. is a global leader i

https://www.chemeurope.com/en/news/301/prometic-and-aventis-behring-sign-a-development-and-collaboration-agreement.html